Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions
Document Type
Article
Department
Radiation Oncology
Abstract
Purpose: TRK fusions are detected in less than 2% of central nervous system tumors. There are limited data on the clinical course of affected patients.
Experimental design: We conducted an international retrospective cohort study of patients with TRK fusion-driven CNS tumors.
Results: 119 patients were identified. The median age at time of diagnosis was 4.5 years. The majority were reported to have a histology consistent with a diagnosis of high-grade glioma (HGG) (57.1%) followed by low-grade glioma (LGG) (27.7%). Pediatric patients had a better prognosis with a median overall survival of 185.5 months compared to 24.8 months in adults (p<.0001). Patients with LGG also had a better outcome when compared to HGG (p=0.0012). The objective response was 68.8% with larotrectinib compared to 38.1% for non-targeted treatment.
Conclusions: Children with LGG glioma had a favorable outcome compared to adult and HGG. TRK inhibitors appear to improve tumor control.
Publication (Name of Journal)
Clinical Cancer Research
DOI
10.1158/1078-0432.CCR-24-0581
Recommended Citation
Lamoureux, A. A.,
Fisher, M. J.,
Lemelle, L.,
Pfaff, E.,
Yazdan, P. A.,
Kramm, C.,
Wilde, B. D.,
Kazanowska, B.,
Hutter, C.,
Mushtaq, N.
(2024). Clinical characteristics and outcome of central nervous system tumors harboring NTRK gene fusions. Clinical Cancer Research.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_radiat_oncol/132
Comments
Volume,issue and pagination are not provided by author/publisher.